Veracyte Analyst Ratings
Expert Ratings For Intellia Therapeutics
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Intellia Therapeutics Analyst Ratings
Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16
Recursion Pharmaceuticals Analyst Ratings
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
10x Genomics GAAP EPS of -$0.32 Beats by $0.16, Revenue of $153.1M Beats by $3.05M
Intellia Hereditary Angioedema Candidate Meets Phase 2 Primary Endpoint
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Cantor Fitzgerald Reiterates Neutral on CRISPR Therapeutics
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
Recursion Pharmaceuticals GAAP EPS of -$0.40 Misses by $0.02, Revenue of $14.42M Beats by $1.13M
Nvidia-backed Recursion to Acquire Exscientia in All-stock Deal
Intellia Therapeutics GAAP EPS of -$1.52 Misses by $0.29, Revenue of $6.96M Misses by $11.29M
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
Beam Therapeutics Analyst Ratings
Intellia Therapeutics Q2 2024 Earnings Preview
Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday
Veracyte Analyst Ratings